Olfactory ensheathing cells in chronic ischemic stroke: A phase 2, double-blind, randomized, controlled trial

Qiao, 2015, Clinical neurorestorative progress in stroke, J Neurorestoratol, 3, 63, 10.2147/JN.S74142 Huang, 2018, Clinical cell therapy guidelines for neurorestoration (IANR/CANR 2017), Cell Transplant, 27, 310, 10.1177/0963689717746999 Chen, 2013, Multiple cell transplantation based on an intraparenchymal approach for patients with chronic phase stroke, Cell Transplant, 22, S83, 10.3727/096368913X672154 Steinberg, 2016, Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke: a phase 1/2a study, Stroke, 47, 1817, 10.1161/STROKEAHA.116.012995 Steinberg, 2018, Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a phase 1/2a study, J Neurosurg, 1, 10.3171/2017.10.JNS17971 Prasad, 2014, Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial, Stroke, 45, 3618, 10.1161/STROKEAHA.114.007028 Hess, 2017, Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial, Lancet Neurol, 16, 360, 10.1016/S1474-4422(17)30046-7 Savitz, 2019, A phase 2 randomized, sham-controlled trial of internal carotid artery infusion of autologous bone marrow-derived ALD-401 cells in patients with recent stable ischemic stroke (RECOVER-stroke), Circulation, 139, 192, 10.1161/CIRCULATIONAHA.117.030659 Lublin, 2014, Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study, Mult Scler Relat Disord, 3, 696, 10.1016/j.msard.2014.08.002 Oh, 2016, A phase III clinical trial showing limited efficacy of autologous mesenchymal stem cell therapy for spinal cord injury, Neurosurgery, 78, 436, 10.1227/NEU.0000000000001056 Rah, 2017, Neuroregenerative potential of intravenous G-CSF and autologous peripheral blood stem cells in children with cerebral palsy: a randomized, double-blind, cross-over study, J Transl Med, 15, 16, 10.1186/s12967-017-1120-0 Levi, 2019, Clinical outcomes from a multi-center study of human neural stem cell transplantation in chronic cervical spinal cord injury, J Neurotrauma, 36, 891, 10.1089/neu.2018.5843 Huang, 2009, Olfactory ensheathing cells transplantation for central nervous system diseases in 1255 patients (in Chinese), Chin J Reparative Reconstr Surg, 23, 14 Huang, 2008, Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients: a controlled pilot study, Clin Transplant, 22, 710, 10.1111/j.1399-0012.2008.00865.x Chen, 2010, Intracranial transplant of olfactory ensheathing cells in children and adolescents with cerebral palsy: a randomized controlled clinical trial, Cell Transplant, 19, 185, 10.3727/096368910X492652 Danielyan, 2009, Intranasal delivery of cells to the brain, Eur J Cell Biol, 88, 315, 10.1016/j.ejcb.2009.02.001 Guo, 2019, Olfactory ensheathing cell transplantation improving cerebral infarction sequela: a case report and literature review, J Neurorestoratol, 7, 82, 10.26599/JNR.2019.9040009 Mao, 2018, Neurorestorative effect of olfactory ensheathing cells and Schwann cells by intranasal delivery for patients with ischemic stroke: design of a multicenter randomized double-blinded placebo-controlled clinical study, J Neurorestoratol, 1, 97, 10.26599/JNR.2018.9040002 Huang, 2006, Influence factors for functional improvement after olfactory ensheathing cell transplantation for chronic spinal cord injury, Chin J Reparative Reconstr Surg, 20, 434 Chen, 2019, Application of olfactory ensheathing cells in clinical treatment of spinal cord injury: meta-analysis and prospect, J Neurorestoratol, 7, 70, 10.26599/JNR.2019.9040008 Holbrook, 2011, Immunohistochemical characterization of human olfactory tissue, Laryngoscope, 121, 1687, 10.1002/lary.21856 Chen, 2014, A prospective randomized double-blind clinical trial using a combination of olfactory ensheathing cells and Schwann cells for the treatment of chronic complete spinal cord injuries, Cell Transplant, 23, S35, 10.3727/096368914X685014 Saberi, 2008, Treatment of chronic thoracic spinal cord injury patients with autologous Schwann cell transplantation: an interim report on safety considerations and possible outcomes, Neurosci Lett, 443, 46, 10.1016/j.neulet.2008.07.041 Saberi, 2011, Safety of intramedullary Schwann cell transplantation for postrehabilitation spinal cord injuries: 2-year follow-up of 33 cases, J Neurosurg: Spine, 15, 515 Zhou, 2012, Transplantation of autologous activated Schwann cells in the treatment of spinal cord injury: six cases, more than five years of follow-up, Cell Transplant, 21, S39, 10.3727/096368912X633752 van Horne, 2018, Peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson's disease during deep brain stimulation surgery: 1-year follow-up study of safety, feasibility, and clinical outcome, J Neurosurg, 129, 1550, 10.3171/2017.8.JNS163222 Yazdani, 2013, Safety and possible outcome assessment of autologous Schwann cell and bone marrow mesenchymal stromal cell co-transplantation for treatment of patients with chronic spinal cord injury, Cytotherapy, 15, 782, 10.1016/j.jcyt.2013.03.012 Oraee-Yazdani, 2016, Co-transplantation of autologous bone marrow mesenchymal stem cells and Schwann cells through cerebral spinal fluid for the treatment of patients with chronic spinal cord injury: safety and possible outcome, Spinal Cord, 54, 102, 10.1038/sc.2015.142 Ramón-Cueto, 1994, Regeneration into the spinal cord of transected dorsal root axons is promoted by ensheathing glia transplants, Exp Neurol, 127, 232, 10.1006/exnr.1994.1099